6 best RTSM solutions for biotech companies in 2026

When you're designing a Phase II trial and your randomization and trial supply management (RTSM) system sits in a separate platform from your electronic data capture (EDC), every kit allocation event becomes a data reconciliation problem. Viedoc's RTSM solution eliminates that friction entirely — randomization and supply management are built directly into the Viedoc eClinical suite, so kit actions are processed in real time, within the same interface your data management team already operates. Across more than 7,000 studies in 75+ countries, Viedoc has become the platform of choice for growth-stage biotech sponsors who need integrated, inspection-ready RTSM that doesn't require a second vendor relationship.

For biotech teams running Phase I and Phase II trials, the RTSM decision is rarely straightforward. You're balancing protocol flexibility — dynamic versus static randomization, multiple treatment arms, mid-study schema changes — against the operational cost of managing yet another vendor, another validation package, and another support escalation path. The stakes are real: a kit shortage that wasn't flagged in time, or a randomization schema that couldn't be updated when enrollment dynamics shifted, can stall a study that's already burning runway.

Enterprise RTSM platforms built for global Phase III programs bring compliance depth, but they arrive with pricing models, implementation timelines, and integration overhead that don't translate well to a lean biotech team navigating a first-in-human or early efficacy study. What this segment needs is a platform that's fast to configure, compliant by design, and operationally integrated with the EDC you're already using — not a second system that requires its own onboarding, contract, and validation cycle.

Best RTSM solutions: quick comparison

Comparing these RTSM platforms for biotech companies

These six RTSM platforms represent the most commonly evaluated options for growth-stage biotech sponsors, reviewed across integration model, randomization flexibility, supply management capability, compliance credentials, and total cost of ownership.

1. Viedoc

Viedoc's Trial Supply Management is the only platform in this comparison where randomization and supply management are natively built into the EDC — not integrated via an API or managed through a partner relationship. Viedoc Randomization supports both static list-based assignments and dynamic algorithm-driven schemes, with multiple concurrent randomizations within a single study. Viedoc Logistics, the supply management layer, manages the full kit lifecycle — registration, allocation, inventory monitoring, expiry tracking, and re-supply alerts — in real time, with no waiting for scheduled system updates.

For biotech teams scaling from a first-in-human to an early-phase efficacy study, the single-platform model eliminates the vendor fragmentation that typically inflates operational overhead. Your data managers configure randomization workflows in Viedoc Designer, execute them in Viedoc Clinic alongside EDC, and monitor kit inventory without logging into a separate system. When Dicot Pharma and CRO Clinical Trial Consultants introduced dynamic randomization for the first time in a 156-patient Phase 2a trial, the integrated Viedoc platform kept the study on its tight timelines — eCRF built and validated in a few weeks, with same-day technical support throughout.

Viedoc's compliance posture covers the full regulatory stack that growth-stage biotech sponsors need: FDA 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, HIPAA, ISO 27001, and SOC 2 Type II. The Viedoc Inspection Readiness Packet (VIRP) is available to all customers as structured audit documentation ahead of regulatory submissions. With 99.99% platform uptime, 24/7 support across global offices, and 40+ languages supported, Viedoc is operationally ready for multi-site international studies at the Phase I/II scale.

"Data handling, reviews, UAT, Query management and the monitoring is a walk in the park, which makes it stand out from other EDCs. Would recommend people to try this application as it is user friendly and appeals to wider individuals with all its colourful and easy to deal with features. Flexible for the programmer and designer to work at the same time. Unblinded randomisation, data import, ePRO, Alerts, RTSM, Logistics." — Deekshitha V., Mid Market

Verified proof points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• User base: 140,000+ users globally; 30,000+ sites
• Integration model: Fully integrated RTSM within the EDC suite; no separate IWRS/IVRS required
• Real-time supply management: Kit actions processed in real time with inventory threshold alerts
• Randomization depth: Static and dynamic randomization; multiple concurrent schemes within a single study
• Compliance: FDA 21 CFR Part 11, GDPR, Annex 11, HIPAA; ISO 27001 and SOC 2 Type II certified
• Inspection readiness: VIRP available to all customers
• Support: 24/7 support across global offices; 40+ languages

2. Medidata

Medidata offers RTSM capabilities within the Medidata platform, which has been used across more than 36,000 trials globally and remains the default choice for large pharma running complex Phase III programs. The Medidata RTSM module supports advanced randomization schemes and global supply chain workflows designed for high-volume, multi-regional studies. Integration with Medidata Rave EDC and other suite modules is native for sponsors already operating on the Medidata platform, providing a single-vendor relationship for large enterprise programs. Medidata is widely recognized by regulatory agencies and procurement teams at large pharma organizations. Its RTSM capabilities are suited to sponsors with complex blinding requirements and large global distribution networks.

For growth-stage biotech sponsors, Medidata's build timelines and pricing model are the primary friction points. Study builds and amendments on Medidata take up to 90 days and require trained programmers for configuration — a dependency that adds cost and delays for lean teams running Phase I and Phase II trials. Medidata's pricing is enterprise-oriented, with per-seat and per-study structures that compound at scale and are typically negotiated through lengthy procurement cycles.

3. Veeva Vault RTSM

Veeva offers RTSM functionality within the Veeva Vault Clinical platform, which integrates EDC, eTMF, CTMS, and supply management under a single ecosystem. The Vault architecture provides seamless connectivity across clinical modules for sponsors who have standardized on Veeva, with zero-downtime updates applicable across the platform. Veeva's RTSM supports an open partner model for supply logistics, with documented integrations including specialist supply management partners. For sponsors already embedded in the Vault ecosystem — particularly those using Vault eTMF or CTMS — adding RTSM within the same platform removes the integration overhead of a separate vendor relationship.

The challenge for growth-stage biotech teams is that Veeva's RTSM value proposition is inseparable from the broader Vault suite. Sponsors who need RTSM alongside EDC but don't already use Vault face a full platform onboarding — complex, expensive, and typically a 6–12-month implementation. Veeva's pricing is enterprise-negotiated, and its support model is oriented toward larger organizations with dedicated vendor management teams.

4. Medrio

Medrio offers an RTSM module alongside its EDC and ePRO capabilities, positioned at Phase I clinics and medical device sponsors operating across 100+ countries. Medrio's platform supports offline data capture, which is relevant for sites in regions with limited connectivity, and its interface is designed to reduce the technical barrier for site staff. Medrio's RTSM is designed to function within its broader Phase I-oriented product set, making it a coherent choice for sponsors running early-phase unit studies where the EDC and RTSM requirements are both served by a single mid-market vendor.

Medrio's platform is less commonly evaluated for more complex Phase II programs where multi-arm randomization schemes, mid-study protocol amendments, or larger supply chain logistics come into scope. Its suite depth — in terms of integrated modules beyond EDC, RTSM, and ePRO — is more limited than platforms with a broader eClinical stack. For biotech sponsors whose trial program will scale beyond early-phase, the platform's roadmap and module range are worth evaluating at RFP stage.

5. 4G Clinical

4G Clinical offers the Prancer IRT platform, a cloud-based interactive response technology system focused on randomization and trial supply management. Prancer functions as a standalone IRT, integrating with third-party EDC systems via API, and is used across a range of trial types including blinded and unblinded studies. 4G Clinical has a documented partner network with eClinical platform vendors, with its system supported for integration alongside several EDC platforms used in commercial biotech trials. The platform supports supply chain workflows including depot management and country-level distribution configurations. As a specialist IRT vendor, 4G Clinical's product focus is narrowly on randomization and supply management rather than the broader eClinical data management workflow.

The primary operational consideration for biotech sponsors evaluating 4G Clinical is the standalone model itself — integrating a specialist IRT with a separate EDC requires API management, parallel validation activities, and two vendor relationships to maintain across the trial lifecycle. This overhead is relevant at RFP stage for smaller biotech teams who are comparing standalone IRT vendors against platforms where RTSM is natively integrated.

What to look for in RTSM solutions for biotech companies

Native integration versus standalone IRT architecture

The most consequential structural question in any RTSM evaluation is whether the system is natively integrated with your EDC or operating as a standalone interactive response technology (IRT) via API. In a natively integrated platform, kit allocation at the point of randomization is instantaneous — the system doesn't wait for an API handshake or scheduled data sync. In a standalone IRT, even well-engineered integrations introduce latency, reconciliation requirements, and a second validation package your QA team needs to qualify. For a Phase II biotech study running tight timelines, that overhead compounds every time you need a protocol amendment or mid-study schema change.

Best-in-class integration means randomization, supply management, and EDC are configured, executed, and audited within a single system under a single validation umbrella. When your data manager executes a randomization in Viedoc's Trial Supply Management solution, the kit allocation is visible in the EDC record immediately — no reconciliation, no waiting.

Overlooking this criterion at the RFP stage is one of the most common sources of post-go-live operational friction for biotech clinical teams.

Randomization schema flexibility and mid-study adaptability

A biotech study rarely runs exactly as the protocol anticipated. Enrollment dynamics shift, stratification variables change, and protocol amendments arrive mid-study. The RTSM platform you choose needs to support not just the schema you designed at study start, but the schema you'll need six months in. Static list-based randomization is the baseline; what separates platforms is their support for dynamic randomization, multiple concurrent randomization schemes within a single study, and the ease with which configurations can be updated without triggering a full system revalidation.

Best-in-class here means on-the-fly configuration updates with full audit trail continuity, and the ability to support both open-label and double-blind protocols within the same system. Look for platforms that allow your team to adjust inventory thresholds and randomization rules directly, without vendor-side programming support. The benchmark question for any vendor is how long a mid-study randomization schema update takes from request to go-live — and whether your team can execute it independently.

Supply chain management depth for lean biotech teams

For a growth-stage biotech running a 100 to 500-patient Phase II study, supply chain complexity looks different from a global Phase III program. You need site-specific inventory thresholds that trigger re-supply alerts before stock shortages affect enrollment, real-time kit registration and allocation, and expiry date tracking that doesn't require manual monitoring. What you don't need is a supply chain platform engineered for 300-site global distribution networks — the configuration overhead alone would consume more resource than your trial logistics team has.

Best-in-class for this segment means a system your supply manager can configure independently, with threshold-based alerts, real-time status across all sites, and support for both primary and supplementary therapy allocation. The operational test is whether the platform can go live within your study build timeline — not on a separate, parallel implementation track.

Compliance architecture and inspection readiness for regulatory submissions

Growth-stage biotech sponsors face a regulatory milestone that enterprise pharma organizations have navigated many times before — and your RTSM platform's compliance posture is part of that story. At a minimum, the platform needs 21 CFR Part 11 compliance for electronic records and signatures, GCP alignment, and GDPR coverage if sites are in Europe. For sponsors preparing for an IND filing or a pre-NDA inspection, the question goes further: does the platform provide structured validation documentation your QA team can submit, and is the audit trail granular enough to satisfy an FDA inspection at the RTSM layer?

Best-in-class means ISO 27001 and SOC 2 Type II certification, a complete electronic audit trail for all randomization and supply management actions, and a structured inspection readiness document available to your team ahead of regulatory interactions. Viedoc's Inspection Readiness Packet (VIRP) is available to all customers as pre-structured audit documentation — not assembled on demand. Platforms that require your team to compile this documentation manually from system exports introduce risk at exactly the moment you can least afford it.

Total cost of ownership beyond the initial contract

Biotech sponsors evaluating RTSM often compare headline license costs without fully accounting for the total cost of operating the system over a two- to three-year study lifecycle. The cost variables that compound are: per-user seat fees as your study team grows, vendor-side programming charges for every schema update or amendment, validation support costs if the platform doesn't provide its own documentation, and the operational time cost of managing two vendor relationships if RTSM is separate from EDC.

Best-in-class pricing means a transparent, study-based licensing model with no per-user fees — so adding a monitor, a sponsor representative, or a site staff member doesn't trigger an incremental license charge. Platforms that bundle RTSM within the EDC license, with no separate RTSM contract, eliminate one of the most common sources of cost surprise in a biotech study. Ask any vendor to walk you through the total cost across the full study lifecycle, including every amendment and schema update your protocol is likely to require.

How to choose the right RTSM solution for your biotech company

Step 1: Define whether you need a standalone IRT or an integrated platform

If your EDC is already selected and contracted, a standalone IRT may be your only option — in which case, the evaluation shifts to integration quality, validation overhead, and vendor reliability. If you're evaluating EDC and RTSM together, an integrated platform is almost always the lower-risk, lower-cost choice. The distinction matters because it determines your validation scope, your vendor management structure, and the support escalation path when something goes wrong mid-study. Committing to a standalone IRT while EDC is still undecided is a sequence risk worth addressing early.

Step 2: Assess your randomization complexity against each platform's configuration model

Document the most complex randomization scenario your current protocol requires — and the most complex scenario it's likely to require if the protocol is amended. Then assess whether each platform's configuration can be updated independently by your team or requires vendor-side programming. For early-phase biotech studies, dynamic randomization with multiple stratification factors is common; the platforms that require a change order and a 4-week implementation cycle for every schema update are not the right fit for your operational reality.

Step 3: Evaluate supply management against your distribution model

Not all biotech studies have complex global supply chains, but most have at least two or three sites in different countries with different inventory needs. Confirm that the platform supports country-specific kit configurations, site-level threshold alerts, and real-time visibility — and that your supply manager can operate these without vendor support. Also confirm what happens when a study runs longer than initially scoped: some platforms charge for extended study access or supply management overruns in ways that aren't visible in the initial contract.

Step 4: Scrutinize the compliance documentation your QA team will need at filing

Ask each vendor for a sample of the validation documentation, audit trail outputs, and inspection readiness materials they provide as standard. If the answer is "we can compile that for you on request," that's a resource cost your QA team will absorb under pressure during a regulatory interaction. Compliance documentation should be a standing deliverable, not a project — and it should be available in a format your regulatory team can use without reformatting.

Step 5: Choose a platform your team can operate and scale without vendor dependency

For a growth-stage biotech running Phase I/II studies, platform independence matters. A system your clinical operations team can configure, amend, and monitor without raising a change order every time the protocol moves is a direct operational advantage. If you're at that evaluation point, Viedoc's Trial Supply Management — natively integrated with Viedoc EDC and ePRO — delivers exactly that model. Book a demo or request a proposal and we'll walk you through a study build in the context of your own protocol.

Frequently asked questions

What is the best RTSM software for biotech companies?

Viedoc's Trial Supply Management is the strongest choice for growth-stage biotech companies running Phase I and Phase II trials. It's natively integrated with Viedoc EDC and ePRO — no separate IWRS or IVRS required — and supports static and dynamic randomization, real-time kit allocation, and site-level inventory management within a single platform. Across 7,000+ studies and 75+ countries, Viedoc has a proven track record with biotech sponsors who need fast study setup, inspection-ready compliance, and a transparent pricing model with no per-user fees. Medidata is the enterprise benchmark for large pharma running complex Phase III programs, but its build timelines and cost structure are a poor fit for lean biotech teams. Veeva Vault RTSM is worth evaluating if your organization has already standardized on the Vault Clinical ecosystem, but comes with full-suite onboarding requirements that extend implementation timelines for organizations buying in for the first time.

What's the difference between RTSM and a standalone IRT platform?

Randomization and trial supply management (RTSM) refers to the combined capability for managing participant randomization and clinical trial kit supply — typically delivered as either a module within an eClinical platform or as a standalone interactive response technology (IRT) system. A standalone IRT integrates with your EDC via an API, which means randomization events and kit allocation actions are reconciled between two systems rather than executed within one. An integrated RTSM module sits within the EDC itself — kit allocation happens in real time at the point of randomization, in the same interface your data manager uses every day. For biotech sponsors, the integrated model reduces vendor complexity, validation overhead, and the operational risk of data reconciliation errors between two separate systems.

How long does it take to set up RTSM for a Phase II biotech trial?

Setup timelines vary considerably by platform and study complexity. On platforms where RTSM is natively integrated with the EDC, study build and randomization configuration can be completed as part of the overall study build cycle — typically 2–4 weeks on Viedoc's platform for a Phase I or Phase II study. Standalone IRT systems require a separate configuration and validation track that runs in parallel with EDC setup, which adds time even when both are running concurrently. Enterprise platforms like Medidata operate on build cycles of up to 90 days, which includes the RTSM configuration. For biotech sponsors working toward a tight first patient in date, the difference in setup time between an integrated and a standalone model is a meaningful operational factor.

What compliance certifications should I look for in an RTSM platform?

At a minimum, your RTSM platform should be compliant with FDA 21 CFR Part 11 for electronic records and signatures, ICH GCP for good clinical practice, and GDPR if any sites are in the European Union. For US-based biotech sponsors filing an investigational new drug (IND) application or preparing for an NDA submission, look for ISO 27001 and SOC 2 Type II certification as evidence of audited information security practices. HIPAA attestation covers US protected health information handling. If your trial includes sites in Japan, APPI compliance is relevant. Beyond certifications, verify that the platform provides structured inspection readiness documentation as a standard deliverable — not assembled on request — and that the electronic audit trail covers all randomization and supply management actions with the granularity an FDA inspection would require.

Can RTSM handle mid-study protocol amendments without full revalidation?

This depends heavily on how the platform's change control architecture is designed. On a well-built integrated platform, mid-study randomization schema updates — adding a stratification factor, adjusting kit allocation rules, or extending an enrollment window — can be applied with a structured version update that maintains full audit trail continuity without triggering a complete system revalidation. The critical question to ask every vendor is what the process looks like for a mid-study amendment: who initiates it, how long it takes, whether it requires vendor-side programming, and whether the audit trail for the prior schema is preserved intact. Platforms that require full revalidation for every schema update, or that require a vendor programmer for each change, impose a cost and timeline burden that matters significantly over a 12- to 24-month Phase II study.

What is the Viedoc Inspection Readiness Packet (VIRP)?

The Viedoc Inspection Readiness Packet (VIRP) is a structured set of pre-prepared audit documentation available to all Viedoc customers. It is designed to support biotech sponsors and CROs preparing for regulatory inspections — including FDA site visits, EMA GCP inspections, and internal QA audits — by providing standardized documentation of the platform's validation status, audit trail architecture, and compliance credentials. Rather than requiring your QA team to assemble inspection documentation from system exports under time pressure, the VIRP is available as a standing resource ahead of regulatory interactions. You can review the VIRP overview or explore Viedoc's security and compliance documentation for full certification details.

Making the right RTSM choice for your biotech company

The RTSM platforms reviewed here span a wide range of deployment models — from fully integrated eClinical suites to specialist standalone IRT systems designed for integration with any EDC. The global eClinical software market is estimated at over $11 billion in 2025 and growing at approximately 14% annually, and the RTSM segment reflects that growth: more biotech sponsors are running complex randomization protocols earlier in the development cycle, and the platform decision has material consequences for go-live timelines, validation costs, and regulatory submission readiness.

Matching a platform to your organization means being honest about three variables: your study complexity relative to what the platform was designed for, your team's capacity to manage vendor relationships versus operating a self-sufficient integrated system, and the compliance requirements of the regulatory agencies you'll face at submission. US biotech sponsors typically weight speed and return on investment heavily; EMEA sponsors often weight compliance documentation depth and vendor stability. Both perspectives are valid inputs into the RFP, and the right platform needs to satisfy both.

Switching RTSM vendors mid-study is an expensive and disruptive exercise that most biotech sponsors learn to avoid the hard way. The validation overhead, data migration risk, and regulatory notification implications of a mid-study platform change are reason enough to invest time in the evaluation upfront — before a go-live commitment locks your clinical operations team into a system that doesn't fit how your trial will actually evolve.

Why Viedoc is the best RTSM choice for biotech companies

For growth-stage biotech sponsors, the core advantage of Viedoc's RTSM solution is structural: randomization and supply management are native to the platform, not bolted on. When a kit is allocated at the point of randomization in Viedoc, that action is recorded in the same audit trail as every other clinical data event — there's no reconciliation between two systems, no latency, and no second validation package. That integrated architecture makes Viedoc operationally different from standalone IRT vendors and from enterprise suites where RTSM is a separate module with its own contract and implementation track.

The operational advantages compound from there. Your clinical team configures randomization schemas and supply thresholds in-house — no vendor-side programming required. With study builds typically completed in 2–4 weeks, you can move from protocol finalization to first patient in faster than enterprise platforms allow. Unlimited user seats mean you can add monitors, sponsor representatives, and site staff without triggering per-seat charges, and Viedoc's transparent, study-based pricing model removes the cost unpredictability that often surprises biotech teams at amendment stage.

Viedoc's compliance posture covers every regulatory dimension that growth-stage sponsors need: FDA 21 CFR Part 11, ICH GCP, GDPR, EU Annex 11, HIPAA attestation, ISO 27001, and SOC 2 Type II certification. The VIRP is available to all customers as pre-structured inspection documentation. Viedoc has been deployed across 7,000+ studies in 75+ countries since its founding in 2003, and 24/7 support across global offices means your clinical team isn't managing support escalations across time zones alone.

If you're evaluating RTSM as part of a broader eClinical platform decision for your next Phase I or Phase II program, book a demo or request a proposal — we'll walk you through randomization configuration, supply management, and compliance credentials in the context of your own study design.